达布拉芬尼
曲美替尼
医学
甲状腺间变性癌
肿瘤科
内科学
MEK抑制剂
化疗
甲状腺癌
威罗菲尼
癌症
MAPK/ERK通路
生物
细胞生物学
激酶
转移性黑色素瘤
作者
Rukiye Arıkan,Tuğba Akın Telli,Nazım Can Demircan,Tuğba Başoğlu,Özlem Ercelep,Beste Melek Atasoy,Salih Özgüven,Faysal Dane,Perran Fulden Yumuk
标识
DOI:10.1016/j.currproblcancer.2020.100668
摘要
Introduction: Anaplastic thyroid carcinoma (ATC) is a highly aggressive, undifferentiated rare tumor. Median overall survival is usually between 8 and10 months, with a 1-year survival rate of 20%. Conventional anthracycline based chemotherapy regimens demonstrate low response rates with short duration. Novel therapeutic agents including BRAF and MEK inhibitors based on the molecular landscape of ATC have been investigated. Case presentation: We herein report the rechallenge of a 52-year-old ATC patient with BRAF V600E mutation with dabrafenib plus trametinib. She presented with recurrent and progressive disease despite surgery, radiation therapy, 3 different chemotherapy regimens, and combination of dabrafenib-trametinib in different settings. She was rechallenged with dabrafenib-trametinib, and had a good response. Conclusion: To our knowledge, this is the first ATC case who responded to dabrafenib-trametinib rechallenge, reported in the literature. We want to emphasize that combination of dabrafenib and trametinib might be a good choice for resistant locoregional and metastatic ATC patients with BRAF V600E mutation, particularly in whom rapid clinical response is urgently needed. Moreover, rechallenge with this combination should be kept in mind in selected cases.
科研通智能强力驱动
Strongly Powered by AbleSci AI